Peptides Logo
Support and counselling under:
+ 49(0)3302 - 2022000 info@peptides.de
€0.00*


EBV (EBNA-3a) Peptide Pool



The EBV (EBNA-3a) Peptide Pool from peptides&elephants is designed for in vitro T cell stimulation and epitope analysis in research on Epstein-Barr virus (EBV, HHV-4). This pool contains 234 synthetic 15-mer peptides, overlapping by 11 amino acids, and spans the complete sequence of EBNA-3a (Epstein-Barr nuclear antigen 3a; UniProt ID: P12977). Each unit enables the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is ideal for use in ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based T cell assays.

Scientific Background

EBV is a ubiquitous herpesvirus that infects more than 90% of the global population. It is the causative agent of infectious mononucleosis and is closely associated with several B cell malignancies, including post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, and Hodgkin lymphoma.

During latency, EBV can enter different gene expression programs. Latency type III, in which all nine latent proteins are expressed, is the only form capable of transforming B cells in vitro, resulting in lymphoblastoid cell lines (LCLs). Among these latency proteins, EBNA-3a plays a supportive but non-essential role in B cell transformation:

  • EBV mutants lacking EBNA-3a can still transform B cells, but with significantly reduced efficiency.
  • EBNA-3a–deficient LCLs proliferate more slowly and show increased apoptosis compared to wild-type virus–derived LCLs.
  • EBNA-3a appears to regulate a subset of cellular genes, some of which overlap with those regulated by EBNA2. The two proteins can act antagonistically or cooperatively to control gene expression.

These findings position EBNA-3a as a key modulator of B cell proliferation and survival during EBV latency, and as a relevant CD8⁺ T cell target in both basic immunological studies and translational research.

Gene:EBNA3
Delivery:1-3 days
Amount:15 nmol/peptide
Counter Ion:TFA
Protein:Epstein-Barr nuclear antigen 3
UniProt Id:P12977
Species:Epstein-Barr virus (EBV; Human herpesvirus 4)
Application :T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication :Infectious disease, Cancer, Neuroscience
Amount/Aliquote :15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 108 cells
Romero-Masters, James C et al. “An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.” Journal of virology vol. 94,10 e02168-19. 4 May. 2020, doi:10.1128/JVI.02168-19

€241.00*

Prices excl. VAT plus shipping costs

Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Product number: LB01361

More EBNA peptides
EBNA 3a (596-604) ( SVRDRLARL )
This peptide represents an HLA-A2-restricted epitope of the Epstein-Barr virus nuclear antigen 3 (EBNA 3). EBNA 3 is a transcriptional regulatory protein that promotes B cell activation through the RBP-Jk pathway. This peptide is used in the study of immunotherapy for solid organ transplant patients.

From €63.50*
Details
EBNA-1 Protein (562-570) ( FMVFLQTHI )
The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalo virus). On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions.

From €63.50*
Details
EBV (EBNA-3a) Peptide Pool
The EBV (EBNA-3a) Peptide Pool from peptides&elephants is designed for in vitro T cell stimulation and epitope analysis in research on Epstein-Barr virus (EBV, HHV-4). This pool contains 234 synthetic 15-mer peptides, overlapping by 11 amino acids, and spans the complete sequence of EBNA-3a (Epstein-Barr nuclear antigen 3a; UniProt ID: P12977). Each unit enables the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is ideal for use in ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based T cell assays. Scientific Background EBV is a ubiquitous herpesvirus that infects more than 90% of the global population. It is the causative agent of infectious mononucleosis and is closely associated with several B cell malignancies, including post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, and Hodgkin lymphoma. During latency, EBV can enter different gene expression programs. Latency type III, in which all nine latent proteins are expressed, is the only form capable of transforming B cells in vitro, resulting in lymphoblastoid cell lines (LCLs). Among these latency proteins, EBNA-3a plays a supportive but non-essential role in B cell transformation: EBV mutants lacking EBNA-3a can still transform B cells, but with significantly reduced efficiency. EBNA-3a–deficient LCLs proliferate more slowly and show increased apoptosis compared to wild-type virus–derived LCLs. EBNA-3a appears to regulate a subset of cellular genes, some of which overlap with those regulated by EBNA2. The two proteins can act antagonistically or cooperatively to control gene expression. These findings position EBNA-3a as a key modulator of B cell proliferation and survival during EBV latency, and as a relevant CD8⁺ T cell target in both basic immunological studies and translational research.

€241.00*
EBV (EBNA-3b) Peptide Pool
Peptide pool of 234 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 4 (EBNA3b) (UniProt ID: Q1HVG4) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€241.00*
EBV EBNA 3A 246-253 (HLA-A*24:02) ( RYSIFFDY )
RYSIFFDY is a linear peptidic epitope (epitope ID 56650) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays

From €63.50*
Details
EBV EBNA 3B 399-408 (HLA-A*11:01) ( AVFDRKSDAK )
Antigen Peptide EBV EBNA3B 399-408 (HLA-A*11:01) AVFDRKSDAK for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €63.50*
Details
EBV EBNA 3C 258-266 (HLA-B*27:02)(HLA-B*27:05)(HLA-B*27:04) ( RRIYDLIEL )
RRIYDLIEL is a linear peptidic epitope (epitope ID55620) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA-1 407-417 (HLA-B*35:01) ( HPVGEADYFEY )
Antigen Peptide EBV EBNA-1 407-417 (HLA-B*35:01) HPVGEADYFEY for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays. HPVGEADYFEY for stimulation of human EBV EBNA-1-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*3501 allele. HPVGEADYFEY is a linear peptidic epitope (epitope ID24536) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €63.50*
Details
EBV EBNA-1 407-417 mutant (HLA-B*35:01) 410A ( HPVAEADYFEY )
EBNA1-derived peptide of HPVAEADYFEY covering 407-417 and B*35:08 molecule. HPVAEADYFEY is a linear peptidic epitope (epitope ID 227777) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €101.50*
Details
EBV EBNA-1 407-417 mutant (HLA-B*35:08) 411D ( HPVGDADYFEY )
EBV EBNA1-derived peptide of HPVGDADYFEY covering 407-417 and B*35:08 molecule. HPVGDADYFEY is a linear peptidic epitope (epitope ID 24525) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €101.50*
Details
EBV EBNA-1 72-80 (HLA-B*35:01) ( RPQKRPSCI )
RPQKRPSCI is a linear peptidic epitope studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays.

From €63.50*
Details
EBV EBNA-1 Peptide Pool
Peptide pool of 158 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 1 (EBNA1) (Uniprot ID: P03211) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€241.00*
EBV EBNA-2 Peptide Pool
Peptide pool of 119 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 2 (EBNA2) (UniProt ID: P12978) of Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€222.00*
EBV EBNA-3A 325-333 (HLA-B*08:01) ( FLRGRAYGL )
Antigen Peptide EBV EBNA3A HLA-B*08:01 (FLRGRAYGL) for stimulation of human EBV EBNA-3A(325-333) -specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0801 allele.

From €63.50*
Details
EBV EBNA-3A 379-387 (HLA-B*07:02) ( RPPIFIRRL )
Antigen Peptide EBV EBNA3A HLA-B*07:02 (RPPIFIRRL) for stimulation of human EBV EBNA-3A (379-387) specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0702 allele.

From €63.50*
Details
EBV EBNA-3A 458-466 (HLA-B*35:01) ( YPLHEQHGM )
HLA-B35-restricted epitope from Epstein-Barr Virus latent nuclear antigen 3A (458-466) for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €63.50*
Details
EBV EBNA-3A 603-611 (HLA-A*03:01) ( RLRAEAQVK )
RLRAEAQVK is a linear peptidic epitope (epitope ID54728) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA-3C 284-293 (HLA-A*02:01) ( LLDFVRFMGV )
LLDFVRFMGV is a linear peptidic epitope (epitope ID 37153) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus) and Other Human herpesvirus 4 (Epstein Barr virus) protein from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA-3C 881-889 (HLA-B*07:02) ( QPRAPIRPI )
QPRAPIRPI is a linear peptidic epitope (epitope ID 51946) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA2 280-290 (DRB1*01:01) ( TVFYNIPPMPL )

From €104.00*
Details
EBV EBNA3A 158-166 (HLA-B*08:01) ( QAKWRLQTL )
QAKWRLQTL is a linear peptidic epitope (epitope ID50298) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01) ( IVTDFSVIK )

From €63.50*
Details
EBV EBNA3C 281-290 (HLA-B*44:05) ( EENLLDFVRF )
EBNA3C-derived peptide of EENLLDFVRF covering 281-290 and B*44:05 molecule. The EBV EBNA3C 281-290 (HLA-B*44:05) peptide recognizes CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. EENLLDFVRF is a linear peptidic epitope (epitope ID11804) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details

More EBV Peptide Pools
EBV (BZLF1) Peptide Pool
Peptide pool of 59 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Trans-activator protein BZLF1 (UniProt ID: P03206) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€222.00*
EBV (EBNA-3a) Peptide Pool
The EBV (EBNA-3a) Peptide Pool from peptides&elephants is designed for in vitro T cell stimulation and epitope analysis in research on Epstein-Barr virus (EBV, HHV-4). This pool contains 234 synthetic 15-mer peptides, overlapping by 11 amino acids, and spans the complete sequence of EBNA-3a (Epstein-Barr nuclear antigen 3a; UniProt ID: P12977). Each unit enables the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is ideal for use in ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based T cell assays. Scientific Background EBV is a ubiquitous herpesvirus that infects more than 90% of the global population. It is the causative agent of infectious mononucleosis and is closely associated with several B cell malignancies, including post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, and Hodgkin lymphoma. During latency, EBV can enter different gene expression programs. Latency type III, in which all nine latent proteins are expressed, is the only form capable of transforming B cells in vitro, resulting in lymphoblastoid cell lines (LCLs). Among these latency proteins, EBNA-3a plays a supportive but non-essential role in B cell transformation: EBV mutants lacking EBNA-3a can still transform B cells, but with significantly reduced efficiency. EBNA-3a–deficient LCLs proliferate more slowly and show increased apoptosis compared to wild-type virus–derived LCLs. EBNA-3a appears to regulate a subset of cellular genes, some of which overlap with those regulated by EBNA2. The two proteins can act antagonistically or cooperatively to control gene expression. These findings position EBNA-3a as a key modulator of B cell proliferation and survival during EBV latency, and as a relevant CD8⁺ T cell target in both basic immunological studies and translational research.

€241.00*
EBV (EBNA-3b) Peptide Pool
Peptide pool of 234 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 4 (EBNA3b) (UniProt ID: Q1HVG4) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€241.00*
EBV (GP350/GP340) Peptide Pool
Peptide pool of 224 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Envelope glycoprotein GP350/GP340 (UniProt ID: P03200) of Epstein-Barr virus (HHV4) One unit allows the stimulation of 2,5 x 108 cells.

€241.00*
EBV (LMP1) Peptide Pool
Peptide pool of 94 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Latent membrane protein 1 (LMP1) (UniProt ID: P03230) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€266.50*
EBV (LMP2) Peptide Pool
The EBV (LMP2) Peptide Pool from peptides&elephants is designed for advanced T cell stimulation and epitope mapping in immunological studies of Epstein-Barr virus (EBV, HHV-4). This peptide pool consists of 122 synthetic 15-mer peptides, overlapping by 11 amino acids, and covers the full sequence of the Latent Membrane Protein 2 (LMP2) (UniProt ID: P13285). LMP2 is a latency-associated antigen commonly expressed in EBV-related malignancies such as nasopharyngeal carcinoma and Hodgkin’s lymphoma. It is a known target of both CD4⁺ and CD8⁺ T cell responses. Each unit of the peptide pool allows for the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is optimized for use in T cell assays, such as ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based functional readouts. Scientific Background LMP2 is one of the most clinically relevant antigens for therapeutic EBV vaccine development, particularly in the context of EBV-associated cancers such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD). Therapeutic vaccine candidates using viral vectors encoding LMP2 have successfully induced virus-specific CD8⁺ T cell responses in early-phase clinical trials. Furthermore, adoptive T cell therapies like posoleucel also target LMP2 alongside other latency proteins such as EBNA1, reinforcing its significance as a conserved and immunodominant antigen. This peptide pool is an ideal tool for: Characterizing patient-specific or vaccine-induced T cell responses Ex vivo stimulation of EBV-specific T cells Epitope screening and immune profiling Immune monitoring in clinical trials of EBV-targeted vaccines or adoptive T cell therapies

€272.50*
EBV (LMP2A) Peptide Pool
Peptide pool of 27 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Latent membrane protein 2A (LMP2A) (UniProt ID: A8CDV5) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€190.00*
Tip
EBV BARF1 Peptide Pool
Peptide pool of 53 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Secreted protein BARF1 (UniProt: P03225) of Homo sapiens Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4). One unit allows the stimulation of 2,5 x 108 cells.

€222.00*
EBV control Peptide Pool (>95% HPLC)
This peptide pool consists of 26 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Epstein-Barr virus (EBV). One unit allows the stimulation of 2,5 x 108 cells.

€190.00*
EBV EBNA-1 Peptide Pool
Peptide pool of 158 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 1 (EBNA1) (Uniprot ID: P03211) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€241.00*
EBV EBNA-2 Peptide Pool
Peptide pool of 119 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 2 (EBNA2) (UniProt ID: P12978) of Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€222.00*

EBV EBNA Peptides
EBNA 3a (596-604) ( SVRDRLARL )
This peptide represents an HLA-A2-restricted epitope of the Epstein-Barr virus nuclear antigen 3 (EBNA 3). EBNA 3 is a transcriptional regulatory protein that promotes B cell activation through the RBP-Jk pathway. This peptide is used in the study of immunotherapy for solid organ transplant patients.

From €63.50*
Details
EBNA-1 Protein (562-570) ( FMVFLQTHI )
The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalo virus). On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions.

From €63.50*
Details
EBV EBNA 3A 246-253 (HLA-A*24:02) ( RYSIFFDY )
RYSIFFDY is a linear peptidic epitope (epitope ID 56650) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays

From €63.50*
Details
EBV EBNA 3B 399-408 (HLA-A*11:01) ( AVFDRKSDAK )
Antigen Peptide EBV EBNA3B 399-408 (HLA-A*11:01) AVFDRKSDAK for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €63.50*
Details
EBV EBNA 3C 258-266 (HLA-B*27:02)(HLA-B*27:05)(HLA-B*27:04) ( RRIYDLIEL )
RRIYDLIEL is a linear peptidic epitope (epitope ID55620) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA-1 407-417 (HLA-B*35:01) ( HPVGEADYFEY )
Antigen Peptide EBV EBNA-1 407-417 (HLA-B*35:01) HPVGEADYFEY for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays. HPVGEADYFEY for stimulation of human EBV EBNA-1-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*3501 allele. HPVGEADYFEY is a linear peptidic epitope (epitope ID24536) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €63.50*
Details
EBV EBNA-1 407-417 mutant (HLA-B*35:01) 410A ( HPVAEADYFEY )
EBNA1-derived peptide of HPVAEADYFEY covering 407-417 and B*35:08 molecule. HPVAEADYFEY is a linear peptidic epitope (epitope ID 227777) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €101.50*
Details
EBV EBNA-1 407-417 mutant (HLA-B*35:08) 411D ( HPVGDADYFEY )
EBV EBNA1-derived peptide of HPVGDADYFEY covering 407-417 and B*35:08 molecule. HPVGDADYFEY is a linear peptidic epitope (epitope ID 24525) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €101.50*
Details
EBV EBNA-1 72-80 (HLA-B*35:01) ( RPQKRPSCI )
RPQKRPSCI is a linear peptidic epitope studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays.

From €63.50*
Details
EBV EBNA-3A 325-333 (HLA-B*08:01) ( FLRGRAYGL )
Antigen Peptide EBV EBNA3A HLA-B*08:01 (FLRGRAYGL) for stimulation of human EBV EBNA-3A(325-333) -specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0801 allele.

From €63.50*
Details
EBV EBNA-3A 379-387 (HLA-B*07:02) ( RPPIFIRRL )
Antigen Peptide EBV EBNA3A HLA-B*07:02 (RPPIFIRRL) for stimulation of human EBV EBNA-3A (379-387) specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0702 allele.

From €63.50*
Details
EBV EBNA-3A 458-466 (HLA-B*35:01) ( YPLHEQHGM )
HLA-B35-restricted epitope from Epstein-Barr Virus latent nuclear antigen 3A (458-466) for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €63.50*
Details
EBV EBNA-3A 603-611 (HLA-A*03:01) ( RLRAEAQVK )
RLRAEAQVK is a linear peptidic epitope (epitope ID54728) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA-3C 284-293 (HLA-A*02:01) ( LLDFVRFMGV )
LLDFVRFMGV is a linear peptidic epitope (epitope ID 37153) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus) and Other Human herpesvirus 4 (Epstein Barr virus) protein from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA-3C 881-889 (HLA-B*07:02) ( QPRAPIRPI )
QPRAPIRPI is a linear peptidic epitope (epitope ID 51946) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA2 280-290 (DRB1*01:01) ( TVFYNIPPMPL )

From €104.00*
Details
EBV EBNA3A 158-166 (HLA-B*08:01) ( QAKWRLQTL )
QAKWRLQTL is a linear peptidic epitope (epitope ID50298) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01) ( IVTDFSVIK )

From €63.50*
Details
EBV EBNA3C 281-290 (HLA-B*44:05) ( EENLLDFVRF )
EBNA3C-derived peptide of EENLLDFVRF covering 281-290 and B*44:05 molecule. The EBV EBNA3C 281-290 (HLA-B*44:05) peptide recognizes CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. EENLLDFVRF is a linear peptidic epitope (epitope ID11804) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €63.50*
Details
This website uses cookies to ensure the best experience possible. More information...